More than 7 million people in the United States have Alzheimer's, and the number of people ⁠aged 65 or older with the disease could exceed ...

Britain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company...

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...

The Dow Jones Industrial Average achieved an all-time high on Wednesday, driven by rising optimism over potential peace talks with Iran. Me...

Major Wall Street indexes opened higher on Wednesday morning. Hopes for Middle East peace offset declines in SpaceX and AMD shares. These c...

European stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased ...

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...

Investors await crucial July employment data and corporate earnings reports this week. Markets are navigating geopolitical tensions and int...

Investors await US employment data and corporate results this week. Market direction remains uncertain due to geopolitical tensions and int...

Alembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of...

Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...

Eli Lilly's acquisition signals a return of psychedelic drugs for mental health. These compounds offer a new approach to rewiring neural co...

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers...

Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo ...

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental...

Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge follow...